Tos Salem M, Shaaban Ahmed, Mantziaris Georgios, Dumot Chloe, Kotecha Rupesh, Fariselli Laura, Gorgulho Alessandra, Levivier Marc, Ma Lijun, Paddick Ian, Pollock Bruce E, Regis Jean, Suh John H, Yomo Shoji, Sahgal Arjun, Sheehan Jason P
Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia, USA.
Department of Neurological Surgery, Hospices civils de Lyon, Lyon, France.
World Neurosurg. 2024 Dec;192:e366-e401. doi: 10.1016/j.wneu.2024.09.106. Epub 2024 Oct 18.
The International Stereotactic Radiosurgery Society aims to establish evidence-based guidelines for single-fraction stereotactic radiosurgery (SRS) in treating intracranial cavernous malformations.
We conducted a systematic review following Preferred Reporting Items for Systematic Reviews and Meta-Analyses and Meta-analysis of Observational Studies in Epidemiology guidelines, searching electronic databases up to January 2024 to assess SRS's impact on post-treatment hemorrhage rates. Pooled risk ratios (RRs) and confidence intervals were used to quantify this effect, along with assessments of lesion volume changes, seizure outcomes, and SRS-related adverse effects.
Our meta-analysis included 32 studies with 2672 patients. A significant decrease in annual hemorrhage rates was observed post-treatment (RR = 0.17), with rates of RR = 0.29 in the first 2 years and RR = 0.11 thereafter. Hemorrhage rates significantly differed before and after 2 years post-SRS (RR = 0.36). Among epileptic patients, 20.2% had epilepsy pretreatment, and 49.9% were seizure-free post-SRS, while 30.6% experienced reduced seizure frequency. Lesion volume changes showed a reduction in 46.9%, stability in 47.1%, and an increase in 6.7%. Symptomatic radiation effects affected 8% of patients. Subgroup analysis revealed symptomatic change rates of 6% at doses ≤13 Gy compared to 9% at doses >13 Gy. Permanent clinical deficits were rare (2%).
This meta-analysis suggests SRS is an effective intervention for intracranial cavernous malformations, significantly reducing hemorrhage rates and improving seizure outcomes. International Stereotactic Radiosurgery Society practice guidelines are provided.
国际立体定向放射外科协会旨在制定基于证据的单分割立体定向放射外科(SRS)治疗颅内海绵状畸形的指南。
我们按照系统评价和Meta分析的首选报告项目以及流行病学观察性研究的Meta分析指南进行了系统评价,检索截至2024年1月的电子数据库,以评估SRS对治疗后出血率的影响。采用合并风险比(RR)和置信区间来量化这种效应,并评估病变体积变化、癫痫发作结果和SRS相关不良反应。
我们的Meta分析纳入了32项研究,共2672例患者。治疗后观察到年出血率显著降低(RR = 0.17),前2年的RR为0.29,此后为RR = 0.11。SRS后2年前后的出血率有显著差异(RR = 0.36)。在癫痫患者中,20.2%的患者治疗前有癫痫,49.9%的患者SRS后无癫痫发作,而30.6%的患者癫痫发作频率降低。病变体积变化显示,46.9%减小,47.1%稳定,6.7%增大。有症状的放射效应影响了8%的患者。亚组分析显示,剂量≤13 Gy时症状变化率为6%,而剂量>13 Gy时为9%。永久性临床缺陷很少见(2%)。
这项Meta分析表明,SRS是治疗颅内海绵状畸形的有效干预措施,可显著降低出血率并改善癫痫发作结果。提供了国际立体定向放射外科协会的实践指南。